title: Comparison of tulathromycin and tilmicosin on the prevalence and severity of bovine respiratory disease in feedlot cattle in association with feedlot performance, carcass characteristics, and economic factors.
abstract: The objectives of this study were to 1) quantify effects of metaphylactic treatment for bovine respiratory disease (BRD) on growth performance, carcass characteristics, and lung lesion prevalence and severity; 2) evaluate the association of lung lesion prevalence and severity with carcass characteristics; and 3) evaluate effects of therapeutic treatment on carcass characteristics and lung lesion prevalence and severity. The study was conducted at a commercial feedlot in the Texas Panhandle in which steers (n = 2,336) initially weighing 312.1 ± 9.6 kg were sourced from auction markets and allocated in a randomized complete block design to 1 of 3 treatments (no metaphylactic [no antimicrobial drug {ND}] treatment, tilmicosin at 10 mg/kg BW [TIL], and tulathromycin at 2.5 mg/kg BW [TUL]). Lungs of all steers were evaluated during harvest to assess presence and severity of pneumonic lesions in the anteroventral lobes and the presence and severity of pleural adherences. Compared to the ND treatment, steers treated via metaphylactic therapy had greater (P < 0.05) metaphylactic cost, ADG, shrunk final BW, dressed carcass yield, HCW, 12th rib fat, calculated empty body fat (EBF), and gross revenue, concurrent with reduced (P < 0.05) BRD treatment costs and financial losses from BRD death and railed cattle, cumulatively resulting in greater financial returns. Lung lesions were present in 64.3% of lungs and were distributed similarly between metaphylactic treatments (63.9%) and ND (65.1%) cattle. Steers with advanced lung lesions present at harvest were associated with reduced (P < 0.05) HCW, KPH, 12th rib fat, calculated yield grades, marbling scores, and calculated EBF as compared to steers without lung lesions. Steers pulled for BRD had increased (P < 0.01) incidence of advanced lung lesions, mortality, and railers with decreased (P < 0.05) HCW, 12th rib fat, KPH, marbling score, calculated EBF, and percentage choice carcasses when compared to non-BRD event steers. From the results of this study, controlling BRD through the use of metaphylactic treatments on arrival in heavier cattle improved financial returns primarily driven by reductions in cost of death loss and railers.
authors.affiliation: Beef Carcass Research Center, West Texas A&M University, Canyon 79016.
authors.forename: T C
authors.initials: TC
authors.lastname: Tennant
authors.affiliation: Cactus Research, Amarillo, TX 79013.
authors.forename: S E
authors.initials: SE
authors.lastname: Ives
authors.affiliation: Beef Strategic Technical Services, Zoetis, Florham Park, NJ 49001.
authors.forename: L B
authors.initials: LB
authors.lastname: Harper
authors.affiliation: Department of Diagnostic Medicine/Pathobiology, College of Veterinary Medicine, Kansas State University, Manhattan 66506-5606.
authors.forename: D G
authors.initials: DG
authors.lastname: Renter
authors.affiliation: Beef Carcass Research Center, West Texas A&M University, Canyon 79016 tlawrence@wtamu.edu.
authors.forename: T E
authors.initials: TE
authors.lastname: Lawrence
mesh_terms: D000273:Adipose Tissue / Q000187:drug effects; D000818:Animals; D000900:Anti-Bacterial Agents / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000662:veterinary; D001823:Body Composition / Q000187:drug effects*; D048090:Bovine Respiratory Disease Complex / Q000191:economics / Q000453:epidemiology* / Q000517:prevention & control; D002417:Cattle / Q000254:growth & development*; D003362:Cost-Benefit Analysis; D004187:Disaccharides / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D006571:Heterocyclic Compounds / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use*; D008168:Lung / Q000473:pathology; D008297:Male; D015995:Prevalence; D011897:Random Allocation; D012720:Severity of Illness Index; D013781:Texas; D016896:Treatment Outcome; D015645:Tylosin / Q000031:analogs & derivatives* / Q000191:economics / Q000494:pharmacology / Q000627:therapeutic use; D018942:Macrolides
chemical_list: D000900:Anti-Bacterial Agents; D004187:Disaccharides; D006571:Heterocyclic Compounds; D015645:Tylosin; C485204:tulathromycin; D018942:Macrolides; C052319:tilmicosin
keywords: bovine respiratory disease; cattle; growth; lung lesion; metaphylaxis